Olanzapine plus modafinil + Olanzapine plus placebo

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Weight Gain

Conditions

Weight Gain

Trial Timeline

Jul 1, 2006 โ†’ Aug 1, 2007

About Olanzapine plus modafinil + Olanzapine plus placebo

Olanzapine plus modafinil + Olanzapine plus placebo is a pre-clinical stage product being developed by Eli Lilly for Weight Gain. The current trial status is completed. This product is registered under clinical trial identifier NCT00636896. Target conditions include Weight Gain.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00636896Pre-clinicalCompleted

Competing Products

20 competing products in Weight Gain

See all competitors
ProductCompanyStageHype Score
Placebo + VK2735Viking TherapeuticsPhase 2
47
VK2735 + Placebo + VK2735 Placebo + VK2735 DrugViking TherapeuticsPhase 1
28
VK2735Viking TherapeuticsPhase 3
72
VK2735 + PlaceboViking TherapeuticsPhase 2
47
VK2735Viking TherapeuticsPhase 3
72
TERN-601Terns PharmaceuticalsPhase 2
49
lorcaserin + phentermine placebo + lorcaserin + phentermine-HCl + phentermine placebo + lorcaserin + phentermine-HClEisaiApproved
85
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
33
LY3305677 + PlaceboEli LillyPhase 1
33
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
33
Exenatide + PlaceboEli LillyApproved
85
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
33
Tirzepatide + AcetaminophenEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
zonisamide + olanzapine + Zonisamide + Sugar Pill (placebo)Eli LillyPhase 3
77
LY3437943 + PlaceboEli LillyPhase 1
33